Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma

References

• Bosch FX, Ribes, J, Diaz, M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127:S5–S16.
   PubMed Web of Science ®Google Scholar
• Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study. Gastroenterology 2004;127:1372–1380.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK 1979–94. Lancet 1997;350:1142–1143.
   PubMed Web of Science ®Google Scholar
• EI-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.
   PubMed Web of Science ®Google Scholar
• Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001;16:553–559.
   PubMed Web of Science ®Google Scholar
• Trevisani F, De Notariis S, Rapaccini, G., Farinati, F., Benvegnù, L., Zoli, M, et al. Italian Liver Cancer Group: Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734–744.
   PubMed Web of Science ®Google Scholar
• Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008;121:119–126.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–90.
   PubMed Web of Science ®Google Scholar
• Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002;62:69–73.
   PubMed Web of Science ®Google Scholar
• Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: analysis of 48 cases. Cancer 2002;95:588–595.
   PubMed Web of Science ®Google Scholar
• Lin CP, Yu HC, Cheng JS, Lai KH, Lo GH, Hsu PI, et al. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc 2004;67(12):602–10.
   PubMedGoogle Scholar
• Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006;106(9):1990–7.
   PubMed Web of Science ®Google Scholar
• Court WS, Order SE, Siegel JA, Johnson E, DeNittis AS, Principato R, et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002;20(5, 6):613–625.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68(5):609–617.
   PubMed Web of Science ®Google Scholar
• Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima, K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159–65.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):248–260.
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57(4):821–9.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Okusaka T, Furuse J, Mitsunaga S, Ueno H, Yamaura H, et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol 2013;72(2):463–70.
   PubMed Web of Science ®Google Scholar
• Song do S, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, et al. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2013;19(29):4679–88.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986;39(2):136–44.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GP Jr. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res 1988;48(13):3869–74.
   PubMed Web of Science ®Google Scholar
• Nagamatsu H, Hiraki M, Mizukami N, Yoshida H, Iwamoto H, Sumie S, et al. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther 2010;32:543.
   PubMed Web of Science ®Google Scholar
• Shinoyama S, Imamura K, Kaminishi M. Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: A phase I study. Int J Clin Oncol 2005;10(4):251–255.
   PubMedGoogle Scholar
• Jeung HC, Rha SY, Noh SH, Roh JK, Chung HC. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. Cancer Chemother Pharmacol 2007;59(3):313–20.
   PubMed Web of Science ®Google Scholar
• Eicher C, Dewerth A, Thomale J, Ellerkamp V, Hildenbrand S, Warmann SW, et al. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. Br J Cancer 2013;108(2):334–41.
   PubMed Web of Science ®Google Scholar
• Chen FS, Cui YZ, Luo RC, Wu J, Zhang H. Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro. Nan Fang Yi Ke Da Xue Bao 2008;28(9):1684–7.
   PubMedGoogle Scholar
• Hagihara A, Ikeda M, Ueno H, Morizane C, Kondo S, Nakachi K, et al. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci 2014;105(3):354–8.
   PubMed Web of Science ®Google Scholar